Bergua Burgués, Juan Miguel | Hematología y Hemoterapia |

Resultados: 297
Tipo Título / Nombre Autor(es) Año
Clinical impact of FLT3 microclones on outcomes in patients with newly diagnosed FLT3-ITD negative AML: A subanalysis from the pethema quiwi trial Sargas C, Boudry A, Lloret Madrid P..., Bergua Burgues JM 2025
Preliminary results from RIVER-81, a phase 2 study of romaciclib (RVU120) + venetoclax in patients with acute myeloid leukemia failing first-line venetoclax + hypomethylating agent (HMA) Montesinos P, Fuente Burguera A de la, García Avila S..., Bergua Burgues JM 2025
Real world outcomes in 355 patients with Acute Myeloid Leukemia arising from chronic myelomonocytic leukemia: A multinational retrospective study Cicconi L, Othman J, Spagnoli A..., Bergua Burgues JM 2025
Golseek-1: A Phase 3, double-blind, randomized study of golcadomide (GOLCA), a potential, ????rst-in-class, oral CELMoDTM agent, + R-CHOP vs placebo + R-CHOP in patients with previously untreated, high-risk, large B-cell lymphoma Vassilakopoulos T, Muñoz J, Huang H..., Bergua Burgues JM 2025
Study design of A phase 3, open-label trial for pozelimab and cemdisiran combination therapy in patients with paroxysmal nocturnal hemoglobinuria with inadequate control of intravascular hemolysis Jang JH, Barrentxea Lekue C, Bergua Burgues JM 2025
Combination of genetics at baseline and clearance of MRD to assign the post-remission treatment of patients with Philadelphia-negative ACUTE lymphoblastic leukemia. FINAL results of pethema LAL19 trial Torrent A, Morgades M Barrera S..., Bergua Burgues JM 2025
Measurable residual disease (MRD) assessment as an early end point oftreatment efficacy in acute myeloid leukemia (AML): A pethema studyof 2,623 patients (Pts) treated with intensive therapy Paiva B, Burgos L, González C..., Bergua Burgues JM 2025
Impact of molecular profile and variant allele frequency in patients with acute myeloid leukemia undergoing allogeneic transplantation in first remission: A study by the pethema group Colmenares R, Barragán E, Rodríguez Veiga R..., Bergua Burgues JM 2025
Combinación del riesgo genético basal y el aclaramiento de la enfermedad residual para asignar el tratamiento post-remisión en los pacientes adultos con leucemia aguda linfoblástica (LAL) sin cromosoma filadelfia (PH-). Resultados finales del protocolo P LAL19 Ribera Santasusana J, Torrent Catarineu A, Morgades De La Fe M, Barrena Delfa S..., Bergua Burgués J 2025
Guía asistencial del Paciente Anciano-Paciente Unfit (Guía PAPU-70+) Montesinos P, Barragán E, Lloret P..., Bergua J, [C. científico y redacción] 2025